SMC accepts glycopyrronium (Seebri BreezhalerT) as a maintenance bronchodilator for COPD

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted glycopyrronium inhalation powder (Seebri BreezhalerT) for use within NHS Scotland as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).   The drug advice (see link below) summarises the safety and efficacy data considered for this drug in this indication. This notes that in two phase III studies, glycopyrronium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks.   Please see the link below for further details.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news